Literature DB >> 19505918

A cohort study of p27 localization in colon cancer, body mass index, and patient survival.

Shuji Ogino1, Kaori Shima, Katsuhiko Nosho, Natsumi Irahara, Yoshifumi Baba, Brian M Wolpin, Edward L Giovannucci, Jeffrey A Meyerhardt, Charles S Fuchs.   

Abstract

Energy balance and the AKT pathway are important in colorectal cancer development and regulate p27 (cyclin-dependent kinase inhibitor-1B/CDKN1B/KIP1), which plays a role in preventing cell cycle progression. However, little is known on the clinical outcome or prognostic significance of p27 alterations in relation to patient body mass index (BMI). Among 630 colon cancers (stage I-IV) in two prospective cohort studies, we detected p27 alterations (cytoplasmic p27 localization or p27 loss) in 500 tumors (79%) by immunohistochemistry. The remaining 130 (21%) tumors were "p27-nuclear+." Cox proportional hazard models computed hazard ratios (HR) of deaths, adjusted for patient and tumoral characteristics, including p53, p21, cyclin D1, KRAS, BRAF, PIK3CA, cyclooxygenase-2, fatty acid synthase (FASN), beta-catenin, microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and long interspersed nucleotide element-1 (LINE-1) hypomethylation. Compared with p27-nuclear+ patients, p27-altered patients experienced low colon cancer-specific [adjusted HR, 0.63; 95% confidence interval (95% CI), 0.42-0.94] and overall mortality (adjusted HR, 0.70; 95% CI, 0.51-0.95), independent of FASN, MSI, CIMP, LINE-1 methylation, and other potential confounders. The effect of p27 alteration on overall mortality significantly differed by BMI (P(interaction) = 0.013); adjusted HR (p27-altered versus p27-nuclear+ tumors) was 0.28 (95% CI, 0.13-0.59) for BMI >or=30 kg/m(2), 0.67 (95% CI, 0.40-1.14) for BMI 25 to 29 kg/m(2), and 0.91 (95% CI, 0.57-1.46) for BMI <25 kg/m(2). Obesity was associated with inferior overall survival among p27-nuclear+ cases (adjusted HR, 3.07; 95% CI, 1.49-6.32; versus nonobese cases), but not among p27-altered cases (adjusted HR, 1.08). In conclusion, p27 alterations in colon cancer are associated with superior prognosis. Adverse prognostic effect of obesity seems limited to patients with nuclear p27 expression, suggesting a host-tumor interaction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505918      PMCID: PMC2769510          DOI: 10.1158/1055-9965.EPI-09-0181

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  54 in total

1.  Absence of the cell cycle inhibitor p27Kip1 protein predicts poor outcome in patients with stage I-III colorectal cancer.

Authors:  C Belluco; G Esposito; R Bertorelle; A Del Mistro; A Fassina; G Vieceli; L Chieco-Bianchi; D Nitti; M Lise
Journal:  Ann Surg Oncol       Date:  1999 Jan-Feb       Impact factor: 5.344

2.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.

Authors:  M Loda; B Cukor; S W Tam; P Lavin; M Fiorentino; G F Draetta; J M Jessup; M Pagano
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

3.  Prognostic significance of p27(kip1) protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas.

Authors:  T Tenjo; M Toyoda; J Okuda; I Watanabe; T Yamamoto; K Tanaka; M Ohtani; T Nohara; H Kawasaki; N Tanigawa
Journal:  Oncology       Date:  2000       Impact factor: 2.935

4.  Analysis of key cell-cycle checkpoint proteins in colorectal tumours.

Authors:  Judith A McKay; Joy J Douglas; Val G Ross; Stephanie Curran; Joseph F Loane; Fareeda Y Ahmed; Jim Cassidy; Howard L McLeod; Graeme I Murray
Journal:  J Pathol       Date:  2002-04       Impact factor: 7.996

5.  Prognostic significance of p27/kip1 and apoptosis in patients with colorectal carcinoma.

Authors:  Tsuyoshi Noguchi; Ryuichi Kikuchi; Kiyoshi Ono; Shinsuke Takeno; Hatsuo Moriyama; Yuzo Uchida
Journal:  Oncol Rep       Date:  2003 Jul-Aug       Impact factor: 3.906

6.  Expression profiling of colorectal carcinomas using tissue microarrays: cell cycle regulatory proteins p21, p27, and p53 as immunohistochemical prognostic markers in univariate and multivariate analysis.

Authors:  Friedrich Prall; Christiane Ostwald; Horst Nizze; Malte Barten
Journal:  Appl Immunohistochem Mol Morphol       Date:  2004-06

7.  Prognostic significance of p27(kip-1) expression in colorectal adenocarcinomas is associated with tumor stage.

Authors:  Upender Manne; Nirag C Jhala; Jennifer Jones; Heidi L Weiss; Chakrapani Chatla; Sreelatha Meleth; Catalina Suarez-Cuervo; William E Grizzle
Journal:  Clin Cancer Res       Date:  2004-03-01       Impact factor: 12.531

8.  RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis.

Authors:  Inti Zlobec; Kristi Baker; Luigi M Terracciano; Alessandro Lugli
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

9.  Mechanisms by which energy restriction inhibits rat mammary carcinogenesis: in vivo effects of corticosterone on cell cycle machinery in mammary carcinomas.

Authors:  Zongjian Zhu; Weiqin Jiang; Henry J Thompson
Journal:  Carcinogenesis       Date:  2003-05-09       Impact factor: 4.944

10.  Determination of molecular marker expression can predict clinical outcome in colon carcinomas.

Authors:  Gennaro Galizia; Eva Lieto; Francesca Ferraraccio; Michele Orditura; Ferdinando De Vita; Paolo Castellano; Vincenzo Imperatore; Ciro Romano; Fortunato Ciardiello; Bruno Agostini; Carlo Pignatelli
Journal:  Clin Cancer Res       Date:  2004-05-15       Impact factor: 12.531

View more
  20 in total

Review 1.  Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field.

Authors:  Shuji Ogino; Andrew T Chan; Charles S Fuchs; Edward Giovannucci
Journal:  Gut       Date:  2010-10-29       Impact factor: 23.059

2.  Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology.

Authors:  Shuji Ogino; Meir Stampfer
Journal:  J Natl Cancer Inst       Date:  2010-03-05       Impact factor: 13.506

3.  Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis.

Authors:  Colin A Flaveny; Kristine Griffett; Bahaa El-Dien M El-Gendy; Melissa Kazantzis; Monideepa Sengupta; Antonio L Amelio; Arindam Chatterjee; John Walker; Laura A Solt; Theodore M Kamenecka; Thomas P Burris
Journal:  Cancer Cell       Date:  2015-06-25       Impact factor: 31.743

4.  Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science.

Authors:  Shuji Ogino; Emily E King; Andrew H Beck; Mark E Sherman; Danny A Milner; Edward Giovannucci
Journal:  Am J Epidemiol       Date:  2012-08-30       Impact factor: 4.897

5.  Recreational physical activity, body mass index, and survival in women with colorectal cancer.

Authors:  Josephina G Kuiper; Amanda I Phipps; Marian L Neuhouser; Rowan T Chlebowski; Cynthia A Thomson; Melinda L Irwin; Dorothy S Lane; Jean Wactawski-Wende; Lifang Hou; Rebecca D Jackson; Ellen Kampman; Polly A Newcomb
Journal:  Cancer Causes Control       Date:  2012-10-02       Impact factor: 2.506

6.  Influence of body mass index on complications and oncologic outcomes following hepatectomy for malignancy.

Authors:  Amit K Mathur; Amir A Ghaferi; Kristen Sell; Christopher J Sonnenday; Michael J Englesbe; Theodore H Welling
Journal:  J Gastrointest Surg       Date:  2010-02-06       Impact factor: 3.452

7.  NRAS mutations are rare in colorectal cancer.

Authors:  Natsumi Irahara; Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Liying Yan; Dora Dias-Santagata; Anthony John Iafrate; Charles S Fuchs; Kevin M Haigis; Shuji Ogino
Journal:  Diagn Mol Pathol       Date:  2010-09

Review 8.  Energy sensing pathways: Bridging type 2 diabetes and colorectal cancer?

Authors:  Juhong Yang; Reiko Nishihara; Xuehong Zhang; Shuji Ogino; Zhi Rong Qian
Journal:  J Diabetes Complications       Date:  2017-04-13       Impact factor: 2.852

9.  Cell Cycle Regulator p27 Mediates Body Mass Index Effects in Ovarian Cancer in FIGO-stages I-II.

Authors:  Ingiridur Skirnisdottir; Helena Akerud; Tomas Seidal; Inger Sundstrom-Poromaa
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

10.  p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis.

Authors:  Shuji Ogino; Katsuhiko Nosho; Kaori Shima; Yoshifumi Baba; Natsumi Irahara; Gregory J Kirkner; Aditi Hazra; Immaculata De Vivo; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-01       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.